<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1501244725
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vyxeos
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAUNORUBICIN,CYTARABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.2,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23892.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER ONCOLOGY GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER ONCOLOGY GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazz Pharmaceutical Ireland Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XY01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vyxeos Liposomal belongs to a group of medicines called &quot;Antineoplastics&rdquo;, which are used in treating cancer. The medicine contains two active substances, Daunorubicin and Cytarabine, in the form of fine particles known as &ldquo;Liposomes&rdquo;.</p><p>The two active substances kill cancer cells in different manners by preventing them from growing and dividing. Packaging these two active substances in the liposomes prolongs their effect on the body and helps them enter and then kill the cancer cells.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vyxeos Liposomal: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to the two active substances (Daunorubicin and Cytarabine) or any other component in this medicine (listed in Section 6).</p><p>&nbsp;</p><p><strong>Warnings and Precautions</strong></p><p>Your doctor will monitor your condition while receiving the treatment. Talk to your doctor, pharmacist, or nurse before you are given Vyxeos Liposomal:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have low platelet count, and low red or white blood cells count (you will undergo a blood test before starting the treatment). If this applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may also give you a medication to help prevent infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also examine you to check for any infection during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have previously had a heart problem or heart attack, or if you have previously taken &ldquo;Anthracyclines&rdquo; for cancer treatment. If this applies to you, your doctor may check your heart before and during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you think you are pregnant. You should use an effective contraception method to avoid pregnancy (you or your partner) during treatment, and for a period of 6 months after the last dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any allergic reactions (hypersensitivity). Your doctor may temporarily or completely stop the treatment, or slow down the intravenous infusion rate, in the event of any hypersensitivity reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered from kidney or liver problems, your doctor will monitor you while taking the treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered from a condition known as Wilson&#39;s disease or other disorders associated with copper accumulation in the body, as Vyxeos Liposomal contains a component known as Copper Gluconate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you will receive a vaccine.</p><p>&nbsp;</p><p>Your doctor will monitor your overall health while receiving the treatment, and he may also give you other medicines to support your treatment, whether before or while receiving the Vyxeos Liposomal treatment. If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist, or nurse before you are given Vyxeos Liposomal.</p><p>&nbsp;</p><p><strong>Children and Adolescents </strong></p><p>Vyxeos Liposomal is not recommended for children and adolescents under the age of 18 years old.</p><p>&nbsp;</p><p><strong>Other Medicines and Vyxeos Liposomal </strong></p><p>Tell your doctor, nurse, or pharmacist if you are using, have recently used, or may be using any other medicines. This is because Vyxeos Liposomal may affect how some other medicines work. In addition, some other medicines may affect how Vyxeos Liposomal works.</p><p>&nbsp;</p><p>Tell your doctor, nurse, or pharmacist if you are taking any of the following medicines, especially:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer medicines that may affect your heart, such as Doxorubicin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that may affect the liver.</p><p>&nbsp;</p><p><strong>Pregnancy, Breastfeeding, and Fertility </strong></p><p>You should not use Vyxeos Liposomal during pregnancy because it may be harmful to the fetus. Use an effective contraception method during treatment and for a period of 6 months after treatment. Tell your doctor immediately if you become pregnant during the treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>You should not breastfeed while being treated with Vyxeos Liposomal, as it can be harmful to the baby.</p><p>&nbsp;</p><p>If you are pregnant or breastfeeding, think you are pregnant or planning to have a baby, consult your doctor before he gives you this medicine.</p><p>&nbsp;</p><p><strong>Driving and Using Machines</strong></p><p>You may feel drowsy or dizzy after taking Vyxeos Liposomal. If this occurs, do not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vyxeos Liposomal must be given to you by a doctor or nurse who is experienced in the AML treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine is given to you as an intravenous injection (intravenous infusion).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous infusion will be given over an hour and a half (90 minutes).</p><p>&nbsp;</p><p>Your doctor, nurse, or pharmacist will determine the medicine&rsquo;s dosage based on your weight and height. Your treatment will be provided in the form of &ldquo;treatment courses&rdquo;. Each course is given in the form of a separate intravenous infusion, and each course may be given weeks apart.</p><p>&nbsp;</p><p>You will receive the first treatment course, and your doctor will decide whether you will receive further treatment courses based on your response to the treatment and the side affects you develop. Your doctor will assess your response to the treatment after each treatment course.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During the first treatment course - you will receive an infusion on days 1, 3 and 5.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In other treatment courses - you will receive an infusion on days 1 and 3. This can be repeated if necessary.</p><p>&nbsp;</p><p>While being treated with Vyxeos Liposomal, your doctor will perform regular blood tests to assess your response to treatment and ensure that it is well-tolerated. Your doctor may also check your heart because Vyxeos Liposomal may affect it.</p><p>&nbsp;</p><p><strong>If you are given more Vyxeos Liposomal doses than you should</strong></p><p>You will be given this medicine at the hospital by your doctor or nurse; so, it is unlikely that you will be given more doses than you should; however, tell your doctor or nurse if you have any concerns.</p><p>&nbsp;</p><p><strong>If you miss the medicine dose</strong></p><p>Call your doctor or nurse as soon as possible.</p><p>&nbsp;</p><p>If you have any other questions about using this medicine, ask your doctor, pharmacist, or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Serious Side effects may appear in more than 1 in 10 people (Very Common)</strong></p><p>Vyxeos Liposomal may reduce the white blood cells count that fight infection, along with reducing the blood cells count that help blood to clot (platelets) thus resulting in bleeding disorders, such as nosebleeds and bruises. Vyxeos Liposomal may also cause heart problems and heart muscle damage.</p><p>&nbsp;</p><p>Therefore, you <strong>must tell your doctor immediately</strong> if you experience any of the following symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, chills, sore throat, cough, mouth ulcers or any other symptoms of infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising without an injury.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain or leg pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&nbsp;</p><p>Tell your doctor immediately if you develop any of the side effects mentioned above.</p><p>&nbsp;</p><p><strong>Other Side Effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very Common</strong> Side Effects (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decline in the platelet count (cells that help blood to clot), which may cause bruising or bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, often accompanied by other signs of infection, due to a very low white blood cell count (Febrile Neutrophils).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow, fast, or irregular heartbeat, and chest pain (which may be a sign of infection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision problems, and blurred vision.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or swelling of the tissues lining the digestive tract (Mucositis), abdominal pain (abdomen), constipation, anorexia, diarrhea, nausea (feeling sick) or vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin redness, rashes, muscle pain, headaches, bone pain, joint pain, fatigue, and general body swelling, including the swelling of the arms and legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness, confusion, difficulty sleeping, and anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough, and fluids in the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure (Hypertension) or low blood pressure (Hypotension).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills, low body temperature, or high body temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating.</p><p>&nbsp;</p><p><strong>Common</strong> Side Effects (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cells count (anemia) leading to fatigue and weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure and abnormal blood tests due to the apoptotic cancer cell death (Tumor Lysis Syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach cramps or excessive gas.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating at night.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&nbsp;</p><p><strong>Uncommon</strong> Side Effects (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness and rash in the hands and feet (Palmar-Plantar Erythrodysesthesia Syndrome).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of Side Effects</strong></p><p>If you have any side effects, talk to your doctor, pharmacist, nurse. This includes any potential side effects that are not included in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton package and vial after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the refrigerator (from 2<sup>o</sup>C to 8<sup>o</sup>C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton package to protect it from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the package in an upright position.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the medicine&rsquo;s reconstitution, the vials must be stored in the refrigerator (2&deg;C to 8&deg;C) for up to 4 hours in an upright position.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After dilution, store the solution in intravenous infusion bags in the refrigerator (2 to 8&deg;C) for up to 4 hours. The maximum combined storage period for both the reconstituted product in a vial stored in an upright position and the reconstituted product after its dilution in the infusion bag should not exceed 4 hours. The duration of the intravenous infusion is 90 minutes; in addition to a storage time of up to 4 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any particles in the diluted solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The two active substances are Daunorubicin and Cytarabine. Each 50 ml vial contains 44 mg Daunorubicin and 100 mg Cytarabine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution, the solution contains 2.2 mg/ml Daunorubicin and 5 mg/ml Cytarabine encapsulated in liposomes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other components are Distearoylphosphatidylcholine (DSPC), Distearoyl Phosphatidylglycerol, Cholesterol, Copper Gluconate, Trolamine, and Sucrose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vyxeos Liposomal is a purple-colored powder, a concentrate for the preparation of the intravenous infusion solution available in a glass vial.

Each pack contains 1 vial, 2 vials, or 5 vials. Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jazz Pharmaceuticals Ireland Ltd</p><p>5th Floor</p><p>Waterloo Exchange</p><p>Waterloo Road</p><p>Dublin</p><p>D04 E5W7</p><p>Ireland</p><p>Tel: +44 8450305089</p><p>E-mail: medinfo-int@jazzpharma.com</p><p>&nbsp;</p><p><strong>Bulk Manufacturer:</strong></p><p>Baxter Oncology GmbH</p><p>Kantstrasse 2</p><p>33790 Halle/Westfalen</p><p>Germany</p><p><strong>&nbsp;</strong></p><p>For any information about this medicinal product, please contact the local representative of the Marketing</p><p>Authorisation Holder:</p><p>&nbsp;</p><p><strong>In the Kingdom of Saudi Arabia (KSA):</strong></p><p>Biologix, FZ Co, Hibatullah Al Ghaffari Street-Suliemaniah Kingdom of Saudi Arabia P.O.Box 991, Riyadh 11421.</p><p>Tel: +966 11 464 6955</p><p>Fax: +966 11 463 4362</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2022.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دواء</strong> <strong>فيكسيوس ليبوزومال؟</strong></p><p dir="RTL">ينتمي دواء فيكسيوس ليبوزومال إلى مجموعة من الأدوية التي يطلق عليها اسم &quot;مضادات الأورام&quot;، والتي تُستخدم في علاج مرض السرطان. ويحتوي الدواء على مادّتين فعّالتين، وهما &quot;داونوروبيسين&quot; و &quot;سيتارابين&quot;، على شكل جسيمات دقيقة تُعرف باسم &quot;جُسيمات شحميّة&quot;.</p><p>&nbsp;</p><p dir="RTL">تعمل المادّتين الفعّالتين على قتل الخلايا السرطانيّة بطرق مختلفة، وذلك من خلال منع تلك الخلايا من النمو والانقسام، ومن ثمّ، فإن تعبئة تلك المادّتين الفعّالتين في جسميات شحميّة يزيد من فترة تأثيرها في الجسم، ويساعدها على دخول الخلايا السرطانيّة ثم قتلها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يُستخدم دواء فيكسيوس ليبوزومال؟</strong></p><p dir="RTL">يُستخدم دواء فيكسيوس ليبوزومال في علاج المرضى المصابين بمرض ابيضاض الدم النقويّ الحادّ المُشخّص حديثًا (سرطان خلايا الدم البيضاء). يتمّ إعطاء الدواء عندما يكون سرطان الدم ناتجًا عن علاجات سابقة (تُعرف باسم العلاج المتعلق بمرض ابيضاض الدم النقويّ الحاد)، أو عندما تكون هناك تغييرات معينة في نخاع العظام (المعروفة باسم مرض ابيضاض الدم النقويّ الحاد مع حدوث &quot;تغيرات مرتبطة بخلل التنسّج النقويّ&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>دواء</strong><strong> </strong><strong>فيكسيوس ليبوزومال: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية ضد المادّتين الفعّالتين (داونوروبيسين وسيتارابين)، أو أيّ من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">سوف يراقب طبيبك حالتك أثناء تلقيك للعلاج. تحدّث إلى طبيبك أو الصيدليّ أو الممرضة قبل أن يتمّ إعطاؤك دواء فيكسيوس ليبوزومال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض عدد الصفائح الدموية وخلايا الدم الحمراء أو البيضاء في دمك (سوف تخضع لفحص دم قبل البدء بتناول العلاج). إذا كان هذا ينطبق عليك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم طبيبك أيضًا بإعطائك دواءً يساعدك في الوقاية من الإصابة بعدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كذلك سوف يقوم طبيبك بفحصك للتحقّق من إصابتك بأيّ عدوى أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت من قبل للإصابة بمشكلة في القلب أو نوبة قلبيّة، أو إذا كنت قد تناولت من قبل أدوية &quot;أنثراسيكلين&quot; الخاصة بعلاج السرطان. إذا كان هذا ينطبق عليك، فقد يقوم طبيبك بإجراء فحص لقلبك قبل البدء في تناول العلاج وأثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعتقدين أنكِ حامل. يجب عليكِ استخدام وسيلة فعالة لمنع الحمل لتجنّب حدوث حمل (أنت أو شريكك) أثناء تناول العلاج، ولمدة 6 أشهر بعد آخر جرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أيّ ردود فعل تحسسيّة (فرط الحساسية)، فقد يوقف طبيبك العلاج لفترة مؤقتة أو يوقفه تمامًا، أو يبطئ معدل التسريب الوريديّ، في حالة حدوث أيّ حالة فرط حساسيّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من مشاكل في الكلى أو الكبد، فسوف يراقبك طبيبك أثناء تناول العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من حالة تعرف باسم مرض ويلسون أو غيره من الاضطرابات المرتبطة بتراكم النحاس في الجسم، حيث يحتوي دواء فيكسيوس ليبوزومال على مكوّن يعرف باسم &quot;غلوكونات النحاس&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستحصل على لقاح.</p><p>&nbsp;</p><p dir="RTL">سوف يقوم طبيبك بمراقبتك لمعرفة حالة صحتك العامة أثناء تلقيك للعلاج، وربما يقوم أيضًا بإعطائك أدوية أخرى لدعم علاجك، سواء كان ذلك قبل تناول دواء فيكسيوس ليبوزومال أو أثناء تلقّي العلاج. إذا كان أيّ مما سبق ينطبق عليك (أو لم تكن متأكدًا)، فتحدّث إلى طبيبك أو الصيدلي أو الممرضة قبل أن يتم إعطاؤك دواء فيكسيوس ليبوزومال.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستخدام<strong> </strong>دواء فيكسيوس ليبوزومال لدى الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>فيكسيوس ليبوزومال والأدوية الأخرى </strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك أو الصيدلي إذا كنت تستخدم أو قد استخدمت مؤخرًا، أو أنك ربما ستستخدم أيّ أدوية أخرى. هذا لأن دواء فيكسيوس ليبوزومال قد يؤثر على طريقة عمل بعض الأدوية الأخرى. كذلك قد تؤثر بعض الأدوية الأخرى على طريقة عمل دواء فيكسيوس ليبوزومال.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو ممرضتك أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التالية، وخاصةً:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أدوية السرطان التي قد يكون لها تأثير على قلبك، مثل: دوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الأدوية التي قد يكون لها تأثير على الكبد.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعيّة والخصوبة</strong></p><p dir="RTL">يجب عليكِ عدم استخدام دواء فيكسيوس ليبوزومال أثناء الحمل لأنه قد يكون ضارًا بالجنين. استخدمي وسيلة فعالة لمنع الحمل خلال العلاج، ولمدة 6 أشهر بعد العلاج. أخبري طبيبك فورًا إذا أصبحتِ حاملًا أثناء العلاج.</p><p>&nbsp;</p><p dir="RTL">يجب عليكِ عدم القيام بالرضاعة الطبيعيّة أثناء تلقيك العلاج باستخدام دواء فيكسيوس ليبوزومال؛ لأنه قد يكون ضارًا بالطفل.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنكِ حامل، أو تخططين لإنجاب طفل، فعليكِ أن تستشيري طبيبك قبل إعطائك هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بالنعاس أو الدوار بعد تناول دواء فيكسيوس ليبوزومال. إذا تعرضت لذلك، فلا تقم بالقيادة أو استخدام أيّ أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتم إعطاؤك دواء فيكسيوس ليبوزومال عن طريق طبيب أو ممرضة لديه/ لديها خبرة في علاج ابيضاض الدم النقويّ الحاد (AML).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء الدواء لك على شكل حقنة في الوريد (تسريب وريديّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء التسريب الوريديّ خلال ساعة ونصف (90 دقيقة).</p><p>&nbsp;</p><p dir="RTL">سوف يقوم طبيبك أو الممرضة أو الصيدليّ بتحديد جرعة الدواء بناءً على وزنك وطولك. سيتم تقديم علاجك في شكل &quot;دورات علاجيّة&quot;. يتمّ إعطاء كل دورة على شكل تسريب وريديّ منفصل، ويمكن أن تفصل بين كل دورة وأخرى أسابيع.</p><p>&nbsp;</p><p dir="RTL">سوف تتلقى الدورة العلاجيّة الأولى، وسوف يقرر طبيبك ما إذا كنت ستتلقى المزيد من الدورات العلاجيّة اعتمادًا على كيفية استجابتك للعلاج وأيّ آثار جانبيّة تظهر لديك. سيقوم طبيبك بتقييم كيفية استجابتك للعلاج بعد كل دورة علاجيّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خلال الدورة العلاجيّة الأولى - سوف تحصل على حقنة في الأيام 1 و 3 و 5.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في الدورات العلاجيّة الأخرى &ndash; سوف تحصل على حقنة في الأيام 1 و3. يمكن تكرار ذلك إذا لزم الأمر.</p><p>&nbsp;</p><p dir="RTL">أثناء تلقيك العلاج بـاستخدام فيكسيوس ليبوزومال، سوف يقوم طبيبك بإجراء فحوصات دم منتظمة من أجل تقييم مدى استجابتك للعلاج، وللتأكد من أنه علاج يمكن تحمّله بشكل جيّد. قد يقوم طبيبك أيضًا بفحص قلبك؛ لأن دواء فيكسيوس ليبوزومال قد يكون له تأثير على القلب.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تمّ إعطاؤك جرعة أكثر مما ينبغي من دواء فيكسيوس ليبوزومال </strong></p><p dir="RTL">سوف يتمّ إعطاؤك هذا الدواء في المستشفى عن طريق الطبيب أو الممرضة. من غير المحتمل أن يتم إعطاؤك جرعة أكثر مما ينبغي، ومع ذلك، أخبر طبيبك أو الممرضة إذا كانت لديك أيّ مخاوف.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا فاتك موعد تناول الدواء </strong></p><p dir="RTL">اتصل بطبيبك أو ممرضتك في أسرع وقت ممكن.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك مزيد من الأسئلة حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدليّ أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في ظهور آثار جانبيّة، على الرغم من عدم ظهورها لدى الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبيّة خطيرة قد تظهر لدى أكثر من 1 من كل 10 أشخاص (شائعة جدًّا)</strong></p><p dir="RTL">قد يعمل دواء فيكسيوس ليبوزومال<strong> </strong>على خفض عدد خلايا الدم البيضاء التي تقاوم العدوى، وكذلك خفض عدد خلايا الدم التي تساعد الدم على التجلّط (الصفائح الدمويّة)، مما يؤدي إلى حدوث اضطرابات النزيف، مثل: نزيف الأنف والكدمات. كذلك قد يتسبب دواء فيكسيوس ليبوزومال<strong> </strong>في ظهور<strong> </strong>مشاكل في القلب، وتلف في عضلة القلب.</p><p>&nbsp;</p><p dir="RTL">لذلك <strong>يجب عليك إخبار طبيبك على الفور</strong>، إذا واجهت أيًّا من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;حمّى، أو قشعريرة، أو التهاب الحلق، أو سعال، أو تقرحات بالفمّ، أو أيّ أعراض أخرى للعدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;نزيف، أو كدمات بدون إصابة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;ألم في الصدر، أو ألم في الساق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;الشعور بضيق في التنفس.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا ظهرت لديك أيّ من الآثار الجانبيّة المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبيّة أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبيّة <strong>شائعة جدًّا</strong> (قد تظهر لدى أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدمويّة (الخلايا التي تساعد على تجلّط الدم)، والتي قد تسبّب في ظهور كدمات أو حدوث نزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمّى، التي غالبًا ما تكون مصحوبة بعلامات أخرى للعدوى، بسبب الانخفاض الشديد في خلايا الدم البيضاء (قلة العدلات الحموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء وسرعة وعدم انتظام ضربات القلب، وألم في الصدر (قد يكون علامة على العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية، تشوّش الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم في الأنسجة المبطنة للجهاز الهضميّ (التهاب الغشاء المخاطيّ)، أو ألم في منطقة البطن (البطن)، أو إمساك، أو فقدان الشهية، أو إسهال، أو غثيان (الشعور بالإعياء)، أو قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، والطفح الجلديّ، وآلام العضلات، والصداع، وآلام العظام، وآلام المفاصل، والتعب، والتورم العام في الجسم، بما في ذلك تورم الذراعين والساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، أو دوار، أو ارتباك، أوصعوبة في النوم، أو قلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس، أو سعال، أو سوائل في الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، أو انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، أو انخفاض في درجة حرارة الجسم، أو ارتفاع في درجة حرارة الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">آثار جانبيّة <strong>شائعة</strong> (قد تظهر لدى 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم)؛ مما يؤدي إلى التعب والضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي، واختبارات الدم غير الطبيعية بسبب الموت الهائل للخلايا السرطانيّة (متلازمة تحلّل الورم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في المعدة، أو غازات مفرطة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرّق المفرط ليلًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبيّة <strong>غير شائعة</strong> (قد تظهر لدى 1 من كل 100 شخص)<strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر، وطفح جلدي في اليدين والقدمين (متلازمة خلل الحسّ الاحمراريّ الراحي الأخمصي).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبيّة</strong></p><p dir="RTL">تحدّث إلى طبيبك أو الصيدلي أو الممرضة إذا ظهرت لديك أيّ آثار جانبيّة، وهذا يشمل ظهور أيّ آثار جانبيّة محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على عبوة الكرتون والقنينة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في الثلاجة (من 2 إلى 8 درجات مئوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالقنينة في العبوة الكرتون الخارجيّة لحمايتها من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خزّن العبوة في وضع رأسيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد إعادة تركيب الدواء، يجب تخزين القنيات في الثلاجة (2 درجة مئوية إلى 8 درجات مئوية) لمدة تصل إلى 4 ساعات في وضع رأسيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التخفيف، عليك تخزين المحلول في أكياس التسريب الوريدي في الثلاجة (من 2 إلى 8 درجات مئوية) لمدة تصل إلى 4 ساعات. يجب ألا يتجاوز الحد الأقصى لوقت التخزين المُجمع، للمنتج المعاد تركيبه في القنية المحفوظة في وضع رأسيّ والمنتج المعاد تركيبه بعد التخفيف في كيس التسريب، 4 ساعات. مدة التسريب الوريدي 90 دقيقة، بالإضافة إلى وقت تخزين يصل إلى 4 ساعات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت أيّ جزيئات في المحلول المخفّف.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>لا ترمِ الأدوية في مياه الصرف الصحيّ. اسأل الصيدليّ حول كيفية التخلّص من الأدوية التي لم تعد بحاجة إليها. حيث إن هذه الإجراءات سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي دواء فيكسيوس ليبوزومال؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادتان الفعالتان هما داونوروبيسين وسيتارابين. تحتوي كل قنينة 50 مل على 44 ملغ دونوروبيسين و100 ملغ سيتارابين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد إعادة التركيب، يحتوي المحلول على 2.2 ملغ/مل دونوروبيسين و 5 ملغ/مل سيتارابين مُغلفة في جسيمات شحميّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ديستيرويل فوسفاتيديل كولين، وديستيرويل فوسفاتيديل جلسرين، والكولسترول، وجلوكونات النحاس، والترولامين والسكروز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو</strong> <strong>دواء فيكسيوس ليبوزومال؟ وما هي محتويات العبوة؟</strong></p><p dir="RTL">دواء فيكسيوس ليبوزومال<strong> </strong>عبارة عن مسحوق أرجواني اللون، وهو رُكازة لتحضير محلول التسريب الوريدي المتوفر في قنينة زجاجيّة.</p><p dir="RTL">تحتوي كل عبوة على 1 قنينة أو 2 قنينة أو 5 قنينات. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق والمصنع المسؤول</strong><strong> عن تحرير الصنف</strong><strong>:</strong></p><p dir="RTL">Jazz Pharmaceuticals Ireland Ltd</p><p dir="RTL">5th Floor</p><p dir="RTL">Waterloo Exchange</p><p dir="RTL">Waterloo Road</p><p dir="RTL">Dublin</p><p dir="RTL">D04 E5W7</p><p dir="RTL">أيرلندا</p><p dir="RTL">هاتف: +44 8450305089</p><p dir="RTL">&nbsp;البريد الإلكتروني: medinfo-int@jazzpharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مصنع الشكل الصيدلاني</strong><strong>:</strong></p><p dir="RTL">Baxter Oncology GmbH</p><p dir="RTL">Kantstrasse 2</p><p dir="RTL">33790 Halle/Westfalen</p><p dir="RTL">Germany</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمزيد من المعلومات حول المنتج الطبي، يُرجى الاتِّصال بالممثل المحلي التابع لمالك رخصة التسويق:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في المملكة العربية السعودية:</strong></p><p dir="RTL">شركة بيولوجكس، شارع هبة الله الغفاري، السليمانية، الممكلة العربية السعودية، ص.ب. 991، الرياض 11421.</p><p dir="RTL">هاتف: 6955 464 11 966+</p><p dir="RTL">فاكس: 4362 463 11 966+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ كانون الثاني 2022 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine.
After reconstitution the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine encapsulated in liposomes in a fixed combination in a 1:5 molar ratio.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
Purple, lyophilised cake.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vyxeos liposomal treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic medicinal products.<br />Vyxeos liposomal has a different posology than daunorubicin injection and cytarabine injection and it must not be interchanged with other daunorubicin and/or cytarabine containing products (see section 4.4).</p><p>Posology<br />Vyxeos liposomal dosing is based on the patient&rsquo;s body surface area (BSA) according to the following schedule:<br />Table 1: Dosing schedule</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:257px">Therapy</td><td style="text-align:center; width:242px">Dosing schedule</td></tr><tr><td style="text-align:center; width:257px">First induction</td><td style="text-align:center; width:242px">daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 on days 1, 3, and 5</td></tr><tr><td style="text-align:center; width:257px">Second induction</td><td style="text-align:center; width:242px">daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 on days 1 and 3</td></tr><tr><td style="text-align:center; width:257px">Consolidation</td><td style="text-align:center; width:242px">daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 on days 1 and 3</td></tr></tbody></table><p>Recommended dosing schedule for induction of remission<br />The recommended dosing schedule of Vyxeos liposomal 44 mg/100 mg/m2, administered intravenously over 90 minutes:<br />&bull; on days 1, 3, and 5 as the first course of induction therapy.<br />&bull; on days 1 and 3 as subsequent course of induction therapy, if needed.</p><p>A subsequent course of induction may be administered in patients who do not show disease progression or unacceptable toxicity. The attainment of a normal-appearing bone marrow may require more than one induction course. Evaluation of the bone marrow following recovery from the previous course of induction therapy determines whether a further course of induction is required. Treatment should be continued as long as the patient continues to benefit or until disease progression up to maximum of 2 induction courses.<br />Recommended dosing schedule for consolidation<br />The first consolidation cycle should be administered 5 to 8 weeks after the start of the last induction.<br />The recommended dosing schedule of Vyxeos liposomal is 29 mg/65 mg/m2, administered intravenously over 90 minutes:<br />&bull; on days 1 and 3 as subsequent courses of consolidation therapy, if needed.</p><p>Consolidation therapy is recommended for patients achieving remission who have recovered to absolute neutrophil count (ANC) &gt; 500/&mu;L and the platelet count has recovered to greater than 50,000/&mu;L in the absence of unacceptable toxicity. A subsequent course of consolidation may be administered in patients who do not show disease progression or unacceptable toxicity within the range of 5 to 8 weeks after the start of the first consolidation. Treatment should be continued as long as the patient continues to benefit or until disease progression, up to maximum of 2 consolidation courses.<br />Recommended dose adjustments during treatment<br />Patients should be monitored for haematologic response and toxicities.<br />Dosing should be delayed or permanently discontinued, if necessary, as described below.<br />Patients may be pre-medicated for nausea and vomiting. An anti-hyperuricemic therapy should be considered (e.g., allopurinol) prior to initiating Vyxeos liposomal.</p><p>Hypersensitivity<br />For mild hypersensitivity symptoms (e.g., mild flushing, rash, pruritus), the treatment should be stopped, and the patient should be supervised, including monitoring of vital signs. The treatment should be restarted slowly once the symptoms have resolved, by halving the rate of infusion and intravenous diphenhydramine (20-25 mg) and intravenous dexamethasone (10 mg) should be given.<br />For moderate hypersensitivity symptoms (e.g., moderate rash, flushing, mild dyspnoea, chest discomfort) the treatment should be stopped. Intravenous diphenhydramine (20-25 mg or equivalent) and intravenous dexamethasone (10 mg) should be given. The infusion should not be restarted. When the patient is retreated, Vyxeos liposomal should be given at the same dose and rate and with premedication.<br />For severe/life-threatening hypersensitivity symptoms (e.g., hypotension requiring vasopressor therapy, angioedema, respiratory distress requiring bronchodilation therapy, generalised urticaria), the treatment should be stopped. Intravenous diphenhydramine (20-25 mg) and dexamethasone (10 mg) should be given, and an epinephrine (adrenaline) or bronchodilators should be added if indicated. Do not reinitiate infusion, and do not retreat. Treatment with Vyxeos liposomal should be permanently discontinued. Patients should be monitored until symptoms resolve (see sections 4.4 and 4.8).</p><p>Missed dose<br />If a planned dose of Vyxeos liposomal is missed, the dose should be administered as soon as possible and the dosing schedule adjusted accordingly, maintaining the treatment interval.<br />Cardiotoxicity<br />Assessment of cardiac function prior to start of treatment is recommended, especially in patients with a high risk of cardiac toxicity. Vyxeos liposomal treatment should be discountinued in patients who develop signs or symptoms of cardiomyopathy, unless the benefits outweigh the risks (see section 4.4).</p><p>Special populations<br />Renal impairment<br />Dose adjustment is not required for patients with mild (creatinine clearance [CrCL] 60 mL/min to 89 mL/min by Cockcroft Gault equation [C-G]) or moderate (CrCL 30 mL/min to 59 mL/min) renal impairment. There is no experience with Vyxeos liposomal in patients with severe renal impairment (CrCL 15 mL/min to 29 mL/min) or end-stage renal disease. Vyxeos liposomal should only be used in patients with severe renal impairment if the benefits outweigh the risks (see sections 4.4 and 5.2).<br />Hepatic impairment<br />Dose adjustment is not required for patients with a bilirubin level less than or equal to 50 &mu;mol/L. There is no experience with Vyxeos liposomal in patients with hepatic impairment resulting in a bilirubin level greater than 50 &mu;mol/L. Vyxeos liposomal should only be used in patients with severe hepatic impairment if the benefits outweigh the risks (see section 4.4).</p><p>Elderly population<br />No dose adjustment is required in elderly patients (&ge;65 years) (see section 5.2).<br />Paediatric population<br />The safety and efficacy of Vyxeos liposomal in children aged 0-18 years have not yet been established. No data are available.</p><p>Method of administration<br />Vyxeos liposomal is for intravenous use only. It must not be administered via an intramuscular, intrathecal, or subcutaneous route.<br />Vyxeos liposomal is administered by intravenous infusion over a period of 90 minutes. Care should be taken to ensure there is no extravasation to prevent the risk of tissue necrosis.<br />For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                History of serious hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Other daunorubicin and/or cytarabine-containing products<br />Vyxeos liposomal must not be substituted or interchanged with other daunorubicin and/or cytarabine containing products. Due to substantial differences in the pharmacokinetic parameters, the dose and schedule recommendations for Vyxeos liposomal are different from those for daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. The medicinal product name and dose should be verified prior to administration to avoid dosing errors.</p><p>Severe myelosuppression<br />Severe myelosuppression (including fatal infections and haemorrhagic events) has been reported in patients after administration of a therapeutic dose of Vyxeos liposomal. Serious or fatal haemorrhagic events, including fatal central nervous system (CNS) haemorrhages, associated with severe thrombocytopenia, have occurred in patients treated with Vyxeos liposomal. Baseline assessment of blood counts should be obtained, and patients should be carefully monitored during treatment with Vyxeos liposomal for possible clinical complications due to myelosuppression. Due to the long plasma half-life of Vyxeos liposomal, time to recovery of ANC and platelets may be prolonged and require additional monitoring.</p><p>Prophylactic anti-infectives (including anti-bacterial, anti-virals, anti-fungals) may be administered during the period of profound neutropenia until ANC returns to 500/&mu;L or greater. If myelosuppressive complications occur, appropriate supportive measures should be used, e.g., anti-infectives, colony-stimulating factors, transfusions. Blood counts should be regularly monitored until recovery (see section 4.8).</p><p>Cardiotoxicity<br />Cardiotoxicity is a known risk of anthracycline treatment. Prior therapy with anthracyclines (including patients who have previously received the recommended maximum cumulative doses of doxorubicin or daunorubicin hydrochloride), pre-existing cardiac disease (including impaired cardiac function), previous radiotherapy of the mediastinum, or concomitant use of cardiotoxic products may increase the risk of daunorubicin-induced cardiac toxicity.</p><p>Total cumulative doses of non-liposomal daunorubicin greater than 550 mg/m2 have been associated with an increased incidence of treatment-induced congestive heart failure. This limit appears lower (400 mg/m2) in patients who received radiation therapy to the mediastinum. The relationship between</p><p>cumulative Vyxeos liposomal dose and the risk of cardiac toxicity has not been determined. Total cumulative exposure of daunorubicin has been described in the table below.</p><p>Table 2: Cumulative exposure of daunorubicin per course of Vyxeos liposomal</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:88px">Therapy</td><td style="text-align:center; width:124px">Daunorubicin per dose</td><td style="text-align:center; width:147px">Number of doses per course</td><td style="text-align:center; width:140px">Daunorubicin per course</td></tr><tr><td style="text-align:center; width:88px">First induction</td><td style="text-align:center; width:124px">44 mg/m2</td><td style="text-align:center; width:147px">3</td><td style="text-align:center; width:140px">132 mg/m2</td></tr><tr><td style="text-align:center; width:88px">Second induction</td><td style="text-align:center; width:124px">44 mg/m2</td><td style="text-align:center; width:147px">2</td><td style="text-align:center; width:140px">88 mg/m2</td></tr><tr><td style="text-align:center; width:88px">Each consolidation</td><td style="text-align:center; width:124px">29 mg/m2</td><td style="text-align:center; width:147px">2</td><td style="text-align:center; width:140px">58 mg/m2</td></tr></tbody></table><p>A baseline cardiac evaluation with an electrocardiogram (ECG) and a multi-gated radionuclide angiography (MUGA) scan or an echocardiography (ECHO) is recommended, especially in patients with risk factors for increased cardiac toxicity. Cardiac function should be closely monitored.<br />Treatment with Vyxeos liposomal should be discontinued in patients with impaired cardiac function unless the benefit of initiating or continuing treatment outweighs the risk (see sections 4.5 and 4.8).<br />Pregnancy warning/women of childbearing potential<br />Patients should be advised to avoid becoming pregnant while receiving Vyxeos liposomal. Male patients and women of childbearing potential must use an effective method of contraception during treatment and for 6 months following the last dose of Vyxeos liposomal (see section 4.6).</p><p>Hypersensitivity reactions<br />Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with daunorubicin and cytarabine.<br />For moderate hypersensitivity symptoms (e.g., moderate rash, flushing, mild dyspnoea, chest discomfort) the treatment should be stopped. Intravenous diphenhydramine (20-25 mg or equivalent) and intravenous dexamethasone (10 mg) should be given. The infusion should not be restarted. When the patient is retreated, Vyxeos liposomal should be given at the same dose and rate and with premedication.<br />For severe/life-threatening hypersensitivity symptoms (e.g., hypotension requiring vasopressor therapy, angioedema, respiratory distress requiring bronchodilation therapy, generalised urticaria), the treatment should be stopped. Intravenous diphenhydramine (20-25 mg) and dexamethasone (10 mg) should be given, and an epinephrine (adrenaline) or bronchodilators should be added if indicated. Do not reinitiate infusion, and do not retreat. Treatment with Vyxeos liposomal should be permanently discontinued. Patients should be monitored until symptoms resolve (see sections 4.2 and 4.8).</p><p>Tissue necrosis<br />Daunorubicin has been associated with local tissue necrosis at the site of medicinal product extravasation. In clinical studies with Vyxeos liposomal, one event of extravasation occurred, but no necrosis was observed. Care should be taken to ensure that there is no extravasation of medicinal product when Vyxeos liposomal is administered. Vyxeos liposomal should be administered intravenously only. Do not administer via an intramuscular, intrathecal, or subcutaneous route (see section 4.2).</p><p>Evaluation of hepatic and renal function<br />Hepatic or renal impairment may increase the risk of toxicity associated with daunorubicin and cytarabine. Evaluation of hepatic and renal function using conventional clinical laboratory tests is recommended prior to administration of Vyxeos liposomal and periodically during treatment. There is no experience with Vyxeos liposomal in patients with baseline serum bilirubin greater than 50 &mu;mol/L, severe renal impairment (creatinine clearance less than 30 mL/min), or end stage renal disease.</p><p>Vyxeos liposomal should only be used in patients with severe hepatic and/or renal impairment if the benefits outweigh the risks (see section 4.2).</p><p>Laboratory tests<br />Vyxeos liposomal may induce hyperuricemia secondary to rapid lysis of leukaemic cells. Blood uric acid levels should be monitored and appropriate therapy initiated in the event that hyperuricemia develops.</p><p>History of Wilson&rsquo;s disease or other copper-related disorder<br />Each vial contains 100 mg of copper gluconate, which corresponds to 14 mg of elemental copper. Vyxeos liposomal should only be used in patients with a history of Wilson&rsquo;s disease or other copper-related disorder if the benefits outweigh the risks (see section 6.1). Discontinue Vyxeos liposomal in patients with signs or symptoms of acute copper toxicity.</p><p>Immunosuppressant effects/Increased susceptibility to infections<br />Administration of live or live-attenuated vaccines in patients that are immunocompromised by chemotherapeutic agents may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving Vyxeos liposomal. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>Gastrointestinal mucositis and diarrhoea<br />It should be taken into consideration that the absorption of oral accompanying medicinal products may be considerably influenced by gastrointestinal mucositis and/or diarrhoea frequently occurring in association with intensive chemotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with Vyxeos liposomal. The delivery of daunorubicin and cytarabine in the Vyxeos liposomal formulation is anticipated to reduce the possibility of interactions, because systemic free-drug concentrations of daunorubicin and cytarabine are much lower than when administered as the non-liposomal formulation.</p><p>Cardiotoxic agents<br />Concurrent use of cardiotoxic agents may increase the risk of cardiotoxicity. Use of Vyxeos liposomal in patients who have previously received doxorubicin increases the risk of cardiotoxicity (see section 4.4). Do not administer Vyxeos liposomal in combination with other cardiotoxic agents unless the patient&#39;s cardiac function is closely monitored.</p><p>Hepatotoxic agents<br />Hepatotoxic medicinal products may impair liver function and increase the toxicity. Since daunorubicin is metabolised by the liver, changes in hepatic function induced by concomitant therapies may affect metabolism, pharmacokinetics, therapeutic efficacy, and/or the toxicity of Vyxeos liposomal (see section 5.2). Hepatic function should be monitored more frequently when Vyxeos liposomal is coadministered with hepatoxic agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential/Contraception in males and females<br />Women of childbearing potential should avoid becoming pregnant while receiving Vyxeos liposomal. Women of childbearing potential should use effective contraception while they or their male partner undergo treatment. Women of childbearing potential should not receive treatment until pregnancy is excluded.</p><p>Women of childbearing potential should undergo pregnancy testing before initiation of Vyxeos liposomal. Men with sexual partners of reproductive potential and women should use effective contraception during treatment and for 6 months following the last dose of Vyxeos liposomal.</p><p>Pregnancy<br />There are no data on the use of Vyxeos liposomal in pregnant women. Based on results from animal studies and its mechanism of action, Vyxeos liposomal should not be used during pregnancy, unless the clinical condition of the woman requires treatment and justifies the potential risk to the foetus (see section 5.3).</p><p>If the medicinal product is used during pregnancy, or if the patient becomes pregnant while receiving Vyxeos liposomal, the woman should be informed of the potential hazard to the foetus. In any case, cardiologic examination and a blood count are recommended in foetuses and newborns born to mothers who received treatment during pregnancy.</p><p>Breast-feeding<br />It is not known whether Vyxeos liposomal is excreted in human milk. Because of the potential for serious adverse reactions in breast-feeding children from Vyxeos liposomal, mothers should be advised to discontinue breast-feeding during Vyxeos liposomal therapy.</p><p>Fertility<br />Based on findings in animals, male fertility may be compromised by treatment with Vyxeos liposomal (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vyxeos liposomal has minor influence on the ability to drive and use machines. Fatigue and dizziness have been reported with the use of Vyxeos liposomal. Therefore, caution is recommended when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most frequently occurring adverse reactions (ADRs) were hypersensitivity including rash (66.9%), febrile neutropenia (63.5%), oedema (52.3%), diarrhoea/colitis (49.9%), mucositis (49.9%), fatigue (46.4%), musculoskeletal pain (44.5%), abdominal pain (36.3%), decreased appetite (33.9%), cough (33.9%), headache (32.3%), chills (31.2%), arrhythmia (30.4%), pyrexia (29.6%), sleep disorders (25.1%), and hypotension (23.7%).</p><p>The most serious and frequently occurring ADRs were infection (58.7%), cardiotoxicity (18.7%) and haemorrhage (13.1%).</p><p>Tabulated list of adverse reactions ADRs have been included under the appropriate category in the table below according to the highest frequency observed in any of the main clinical studies.</p><p>Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. For classification of ADRs which occur at Grades 3-5, a comprehensive listing is available from the NCI at NCI CTCAE. Toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality.</p><p>Table 3: ADRs reported in clinical studies in patients treated with Vyxeos liposomal (n=375)</p><table border="1" cellspacing="1" cellpadding="1" style="width:541px"><tbody><tr><td style="text-align:center; width:222px">System Organ Class</td><td style="text-align:center; width:222px">ADRs/Frequency (%)</td><td style="text-align:center; width:182px">Grade 3-5 ADRs/Frequency (%)</td></tr><tr><td style="text-align:center; width:222px">Infections and infestations</td><td style="width:222px"><p style="text-align:center">Very Common</p><p style="text-align:center">Infection (78.1)</p></td><td style="width:182px"><p style="text-align:center">Very Common</p><p style="text-align:center">Infection (58.7)</p></td></tr><tr><td style="text-align:center; width:222px">Blood and lymphatic system disorders</td><td style="width:222px"><p style="text-align:center">Very Common<br />Febrile neutropenia (63.5)</p><p style="text-align:center">Common<br />Thrombocytopenia (4.5)<br />Neutropenia (3.7)<br />Anaemia (3.2)</p></td><td style="width:182px"><p style="text-align:center">Very Common<br />Febrile neutropenia (62.4)</p><p style="text-align:center">Common<br />Thrombocytopenia (3.7)<br />Neutropenia (3.5)<br />Anaemia (2.1)</p></td></tr><tr><td style="text-align:center; width:222px">Immune systems disorders</td><td style="text-align:center; width:222px">Very Common<br />Hypersensitivity (including rash) (66.9)</td><td style="text-align:center; width:182px">Common<br />Hypersensitivity (including rash) (9.1)</td></tr><tr><td style="text-align:center; width:222px">Metabolism and nutrition disorders</td><td style="text-align:center; width:222px">Common<br />Tumour lysis syndrome (7.5)</td><td style="text-align:center; width:182px">Common<br />Tumour lysis syndrome (2.7)</td></tr><tr><td style="text-align:center; width:222px">Psychiatric disorders</td><td style="text-align:center; width:222px">Very Common<br />Sleep disorders (25.1)<br />Anxiety (17.3)<br />Delirium (15.5)</td><td style="text-align:center; width:182px">Common<br />Delirium (2.4)<br />Uncommon<br />Sleep disorders (0.5)</td></tr><tr><td style="text-align:center; width:222px">Nervous system disorders</td><td style="text-align:center; width:222px">Very Common<br />Headache (32.3)<br />Dizziness (23.2)</td><td style="text-align:center; width:182px">Common<br />Headache (1.1)<br />Uncommon<br />Dizziness (0.8)</td></tr><tr><td style="text-align:center; width:222px">Eye disorders</td><td style="text-align:center; width:222px">Very Common<br />Visual impairment (10.4)</td><td style="text-align:center; width:182px">Uncommon<br />Visual impairment (0.3)</td></tr><tr><td style="text-align:center; width:222px">Cardiac disorders</td><td style="text-align:center; width:222px">Very Common<br />Cardiotoxicity (72)<br />Arrhythmiaa (30.4)<br />Chest pain (17.6)</td><td style="text-align:center; width:182px">Very Common<br />Cardiotoxicity (18.7)<br />Common<br />Arrhythmiaa (4.3)<br />Chest pain (1.9)</td></tr><tr><td style="text-align:center; width:222px">Vascular disorders</td><td style="text-align:center; width:222px">Very Common<br />Haemorrhage (69.1)<br />Hypotension (23.7)<br />Hypertension (17.3)</td><td style="text-align:center; width:182px">Very Common<br />Haemorrhage (13.1)<br />Common<br />Hypertension (6.9)<br />Hypotension (4.5)</td></tr><tr><td style="text-align:center; width:222px">Respiratory, thoracic and mediastinal disorders</td><td style="text-align:center; width:222px">Very Common<br />Dyspnoea (36.5)<br />Cough (33.9)<br />Pleural effusion (13.9)</td><td style="text-align:center; width:182px">Very Common<br />Dyspnoea (13.1)<br />Uncommon<br />Pleural effusion (0.8)</td></tr><tr><td style="text-align:center; width:222px">Respiratory, thoracic and mediastinal disorders</td><td style="text-align:center; width:222px">Very Common<br />Dyspnoea (36.5)<br />Cough (33.9)<br />Pleural effusion (13.9)</td><td style="text-align:center; width:182px">Very Common<br />Dyspnoea (13.1)<br />Uncommon<br />Pleural effusion (0.8)</td></tr><tr><td style="text-align:center; width:222px">Gastrointestinal disorders</td><td style="width:222px"><p style="text-align:center">Very Common<br />Nausea (51.7)<br />Diarrhoea/colitis (49.9)<br />Mucositis (49.9)<br />Constipation (42.7)<br />Abdominal pain (36.3)<br />Decreased appetite (33.9)<br />Vomiting (27.7)</p><p style="text-align:center"><br />Common<br />Dyspepsia (9.6)</p></td><td style="width:182px"><p style="text-align:center">Common<br />Diarrhoea/colitis (6.1)<br />Abdominal pain (2.9)<br />Mucositis (2.1)<br />Decreased appetite (1.6)<br />Constipation (1.1)<br />Nausea (1.1)</p><p style="text-align:center">Uncommon<br />Dyspepsia (0.5)<br />Vomiting (0.3)</p></td></tr><tr><td style="text-align:center; width:222px">Skin and subcutaneous tissue disorders</td><td style="width:222px"><p style="text-align:center">Very Common<br />Pruritus (17.3)<br />Hyperhidrosis (10.1)</p><p style="text-align:center">Common<br />Night sweats (8.3)<br />Alopecia (3.2)<br />Uncommon<br />Palmar-plantar erythrodysaesthesia syndrome (0.8)</p></td><td style="text-align:center; width:182px">Uncommon<br />Hyperhidrosis (0.3)</td></tr><tr><td style="text-align:center; width:222px">Musculoskeletal and connective tissue disorders</td><td style="text-align:center; width:222px">Very Common<br />Musculoskeletal pain (44.5)</td><td style="text-align:center; width:182px">Common<br />Musculoskeletal pain (5.1)</td></tr><tr><td style="text-align:center; width:222px">Renal and urinary disorders</td><td style="text-align:center; width:222px">Very Common<br />Renal insufficiency (10.4)</td><td style="text-align:center; width:182px">Common<br />Renal insufficiency (6.4)</td></tr><tr><td style="text-align:center; width:222px">General disorders and administration site conditions</td><td style="text-align:center; width:222px">Very Common<br />Oedema (52.3)<br />Fatigue (46.4)<br />Chills (31.2)<br />Pyrexia (29.6)</td><td style="width:182px"><p style="text-align:center">Very Common<br />Fatigue (10.4)</p><p style="text-align:center">Common<br />Pyrexia (3.2)<br />Oedema (2.7)</p><p style="text-align:center">Uncommon<br />Chills (0.3)</p></td></tr><tr><td style="width:222px">&nbsp;</td></tr></tbody></table><p>a Arrhythmia group terms includes atrial fibrillation, bradycardia, and the most commonly reported arrhythmia was tachycardia</p><p>Description of selected adverse reactions</p><p>Infections<br />Due to the neutropenia experienced with Vyxeos liposomal, infections of various types were very common ADRs. Pneumonia, sepsis and bacteriaemia were the most frequently seen serious infection ADRs in the clinical studies population. The incidence of infection events was 78.1%; the incidence of non-serious events of infections was 73.1%, the incidence of serious events of infections was 28.5%; the incidence of infections which led to discontinuation is 0.5%. The incidence of fatal infections was 6.9%. The fatal infections experienced were sepsis and pneumonia (see section 4.4).</p><p>Haemorrhage<br />Due to the thrombocytopenia experienced with Vyxeos liposomal a variety of haemorrhagic events were seen in clinical studies. The most common haemorrhagic event was epistaxis, and the majority of these were considered not serious (29.1%). The incidence of haemorrhage events is 69.1%; the incidence of non-serious events of haemorrhage was 67.2 %; the incidence of serious events of haemorrhage is 5.6%; the incidence of haemorrhage which led to discontinuation is 0. The incidence of fatal haemorrhage was 2.1%. Serious or fatal haemorrhagic events, including fatal central nervous system (CNS) haemorrhages, associated with severe thrombocytopenia were seen in patients treated with Vyxeos liposomal (see section 4.4).</p><p>Cardiotoxicity<br />Cardiotoxicities were seen in Vyxeos liposomal clinical studies. The most frequently reported serious ADRs were decreased ejection fraction and congestive cardiac failure. Cardiotoxicity is a known risk of anthracycline treatment. The incidence of all cardiotoxicity events was 72.0%; the incidence of non-serious events of cardiotoxicity was 68.5 %; the incidence of serious events of cardiotoxicity was 9.1%; the incidence of cardiotoxicity which led to discontinuation is 0. 5%. Incidence of fatal cardiotoxicity events is 0.5%. Cardiac arrest was reported as a fatal event; the patient experienced thrombocytopenia and neutropenia which contributed to cardiac arrest (see section 4.4).</p><p>Hypersensitivity<br />Hypersensitivity reactions were very common ADRs in Vyxeos liposomal clinical studies. The most frequently reported hypersensitivity ADRs were rash and the majority of these were not serious (38.9%). The incidence of all hypersensitivity events was 66.9%; the incidence of non-serious events of hypersensitivity was 66.4 %, of which 38.9 % were rash; the incidence of serious events of hypersensitivity is 1.1%; the frequency of hypersensitivity which led to discontinuation is 0. The frequency of fatal hypersensitivity events was 0 (see section 4.4).</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>To reports any side effect(s):</p><p>Saudi Arabia:</p><ul><li>The National Pharmacovigilance Centre (NPC):</li></ul><p>-SFDA Call Center: 19999<br />- E-mail : npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p>Other GCC States:</p><p>-Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific experience in the management of overdose in patients. If overdose occurs, exacerbation of adverse reactions associated with Vyxeos liposomal are expected and supportive treatment (incuding anti-infectives, blood and platelet transfusions, colony-stimulating factors, and intensive care as needed) should be provided until the patient recovers. Observe the patient carefully over time for signs of cardiotoxicity and provide appropriate supportive therapy as clinically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, combinations of antineoplastic agents, ATC code: L01XY01.</p><p>Mechanism of action<br />Vyxeos liposomal is a liposomal formulation of a fixed combination of daunorubicin and cytarabine in a 1:5 molar ratio. The 1:5 molar ratio has been shown in vitro and in vivo to maximise synergistic antitumour activity in AML.</p><p>Daunorubicin has antimitotic and cytotoxic activity, which is achieved by forming complexes with DNA, inhibiting topoisomerase II activity, inhibiting DNA polymerase activity, affecting regulation of gene expression, and producing DNA-damaging free radicals.</p><p>Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA synthesis. Incorporation into DNA and RNA</p><p>may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to proliferating mammalian cells in culture.</p><p>Vyxeos liposomal liposomes exhibit a prolonged plasma half-life following intravenous infusion, with greater than 99% of the daunorubicin and cytarabine in the plasma remaining encapsulated within the liposomes. Vyxeos liposomal delivers a synergistic combination of daunorubicin and cytarabine to leukaemia cells for a prolonged period of time. Based on data in animals, Vyxeos liposomal liposomes accumulate and persist in high concentration in the bone marrow, where they are preferentially taken up intact by leukaemia cells in an active engulfment process. In leukaemia-bearing mice, the liposomes are taken up by leukaemia cells to a greater extent than by normal bone marrow cells. After internalisation, Vyxeos liposomal liposomes undergo degradation, releasing daunorubicin and cytarabine within the intracellular environment, enabling the medicinal products to exert their synergistic antineoplastic activity.</p><p>Clinical efficacy and safety<br />The efficacy of Vyxeos liposomal in adults for the treatment of newly diagnosed AML was evaluated in one controlled clinical study (Study 301).</p><p>Study 301 in patients with untreated high risk AML<br />Study 301 was a Phase 3 randomised, multicentre, open-label, parallel-arm, superiority study which evaluated Vyxeos liposomal vs. a standard combination of cytarabine and daunorubicin (7+3) in 309 patients between 60 to 75 years of age with untreated high risk AML. Patients with the following AML sub-types were included in the study: therapy-related AML (t-AML), myelodysplastic syndrome AML (MDS AML) and chronic myelomonocytic leukaemia AML (CMMoL AML) with documented history of MDS or CMMoL prior to transformation to AML, and de novo AML with karyotype changes characteristic of myelodysplasia, (per 2008 WHO criteria).</p><p>The study included 2 phases, 1) Treatment Phase during which patients received up to 2 induction and 2 consolidation courses, and 2) a Follow-up Phase, which began 30 days after the last induction or consolidation course and continued for up to 5 years from randomisation. The number of inductions and consolidations a patient received depended upon Complete Response (CR) or Complete Response with incomplete recovery (CRi), which was confirmed by bone marrow assessment. In clinical studies only, Vyxeos liposomal 100 units/m2/day (equivalent to 44 mg/100 mg/m2) was administered intravenously over 90 minutes on days 1, 3, and 5 for the first induction and on days 1 and 3 for patients requiring a second induction. A second induction was highly recommended for patients who did not achieve a CR or CRi in the first induction course and was mandatory for patients achieving greater than 50% reduction in percent blasts. Post-remission therapy with haematopoietic stem cell transplantation (HSCT) was permitted either in place of or after consolidation chemotherapy. For consolidation courses, in clinical studies only, the Vyxeos liposomal dose was reduced to 65 units/m2/day (equivalent to 29mg/65 mg/m2) on days 1 and 3. In the 7+3 arm, first induction consisted of cytarabine 100 mg/m2/day on days 1 to 7 by continuous infusion, and daunorubicin 60 mg/m2/day on days 1, 2, and 3 whereas second induction and consolidation cytarabine was dosed on days 1 to 5 and daunorubicin on days 1 and 2.</p><p>There were 153 patients randomised to Vyxeos liposomal and 156 patients randomised to the 7+3 control arm. The randomised patients had a median age of 68 (range 60-75 years), 61% were male, and 88% had an ECOG performance status of 0-1. At baseline 20% had t-AML, 54% had AML with an antecedent haematological disorder and 25% had de novo AML with myelodysplasia-related cytogenetic abnormalities; 34% had been treated previously with a hypomethylating agent for MDS;54% had an adverse karyotype.</p><p>The demographic and baseline disease characteristics were generally balanced between the study arms. FLT3 mutation was identified in 15% (43/279) of patients tested and NPM1 mutation was identified in 9% (25/283) patients tested.</p><p>The primary endpoint was overall survival measured from the date of randomisation to death from any cause. Vyxeos liposomal demonstrated superiority in overall survival in the ITT population compared</p><p>with the comparator 7+3 treatment regimen (Figure 1). The median survival for the Vyxeos liposomal treatment group was 9.56 months compared with 5.95 months for the 7+3 treatment group (Hazard Ratio = 0.69, 95% CI = 0.52, 0.90, two-sided log-rank test p = 0.005).<br />The overall rate of HSCT was 34% (52/153) in the Vyxeos liposomal arm and 25% (39/156) on the control arm.</p><p>Figure 1: Kaplan-Meier curve for overall survival, ITT population</p><p><img alt="" width="981" height="539" src="data:image/jpeg;base64,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" /></p><p>Table 4: Efficacy results for study 301</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:197px">&nbsp;</td><td style="text-align:center; width:168px">Vyxeos liposomal<br />N=153</td><td style="text-align:center; width:134px">7+3<br />N=156</td></tr><tr><td colspan="3" style="text-align:center">Overall survival</td></tr><tr><td style="text-align:center; width:197px">Median survival, months (95% CI)</td><td style="text-align:center; width:168px">9.56 (6.60, 11.86)</td><td style="text-align:center; width:134px">5.95 (4.99, 7.75)</td></tr><tr><td style="text-align:center; width:197px">Hazard ratio (95% CI)</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">&nbsp;0.69 (0.52, 0.90)</td></tr><tr><td style="text-align:center; width:197px">p-value (2-sided) a</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">&nbsp;0.005</td></tr><tr><td colspan="3" style="text-align:center; width:197px">Event free survival</td></tr><tr><td style="text-align:center; width:197px">Median survival, months (95% CI)</td><td style="text-align:center; width:168px">2.53 (2.07, 4.99)</td><td style="text-align:center; width:134px">1.31 (1.08, 1.64)</td></tr><tr><td style="text-align:center; width:197px">Hazard ratio (95% CI)</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">0.74 (0.58, 0.96)</td></tr><tr><td style="text-align:center; width:197px">p-value (2-sided) a</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">0.021</td></tr><tr><td>Complete response rate</td></tr><tr><td style="text-align:center; width:197px">CR, n (%)</td><td style="text-align:center; width:168px">57 (37)</td><td style="text-align:center; width:134px">40 (26)</td></tr><tr><td style="text-align:center; width:197px">Odds ratio (95% CI)</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">&nbsp;1.69 (1.03, 2.78)</td></tr><tr><td style="text-align:center; width:197px">p-value (2-sided) b</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">&nbsp;0.040</td></tr><tr><td style="text-align:center; width:197px">CR + CRi, n (%)</td><td style="text-align:center; width:168px">73 (48)</td><td style="text-align:center; width:134px">52 (33)</td></tr><tr><td style="text-align:center; width:197px">Odds ratio (95% CI)</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">1.77 (1.11, 2.81)</td></tr><tr><td style="text-align:center; width:197px">p-value (2-sided) b</td><td rowspan="1" colspan="2" style="text-align:center; width:168px">0.016</td></tr></tbody></table><p>Abbreviations: CI = Confidence interval; CR= Complete response; CRi= Complete response with incomplete recovery<br />a p-value from stratified log rank test stratifying by age and AML sub-type<br />b p-value from stratified Cochran-Mantel-Haenszel test stratified by age and AML sub-type</p><p>60 Month Follow-up<br />The 60 month overall survival rate was higher for the Vyxeos liposomal treatment arm (18%) versus the 7+3 treatment arm (8%); the hazard ratio was 0.70, 95% CI= 0.55, 0.91.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Vyxeos liposomal in one or more subsets of the paediatric population in AML (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of daunorubicin and cytarabine administered as Vyxeos liposomal were investigated in adult patients who received a dose of daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered as a 90-minute intravenous infusion on days 1, 3, and 5. The pharmacokinetics of each medicinal product was based on total plasma concentrations (i.e., encapsulated plus unencapsulated medicinal product). Following the dose administered on day 5, the mean (% coefficient of variation [CV]) maximum plasma concentrations (Cmax) for daunorubicin was 26.0 (32.7%) mcg/mL and cytarabine was 62.2 (33.7%) mcg/mL. The mean (%CV) area under the curve (AUC) during one dosing interval for daunorubicin was 637 (38.4%) mcg.h/mL and cytarabine was 1900 (44.3%) mcg.h/mL.</p><p>When daunorubicin and cytarabine are administered as components of Vyxeos liposomal, the liposomes appear to govern their tissue distribution and rates of elimination; therefore, while the non-liposomal medicinal products have markedly different clearance (CL), volume of distribution (V), and terminal half-life (t1/2) Vyxeos liposomal causes these pharmacokinetic parameters to converge.</p><p>The accumulation ratio was 1.3 for daunorubicin and 1.4 for cytarabine. There was no evidence of time-dependent kinetics or major departures from dose proportionality over the range of 1.3 mg/3 mg per m2 to 59 mg/134 mg per m2 (0.03 to 1.3 times the approved recommended dosage).</p><p>Distribution<br />The volume of distribution (%CV) for daunorubicin is 6.6 L (36.8%) and cytarabine is 7.1 L (49.2%). Plasma protein binding was not evaluated.</p><p>Metabolism and biotransformation<br />Similar to non-liposomal daunorubicin and cytarabine, subsequent to release from Vyxeos liposomal liposomes, both daunorubicin and cytarabine are extensively metabolised in the body. Daunorubicin is mostly catalysed by hepatic and non-hepatic aldo-keto reductase and carbonyl reductase to the active metabolite daunorubicinol. Cytarabine is metabolised by cytidine deaminase to the inactive metabolite 1-&beta; (beta)-D-arabinofuranosyluracil (AraU). Unlike non-liposomal daunorubicin and cytarabine, which are quickly metabolised to the respective metabolites, daunorubicin and cytarabine after Vyxeos liposomal administration are free bases encapsulated in liposomes. Plasma concentration-time profiles obtained from 13 to 26 patients who received Vyxeos liposomal 100 units/m2 (equivalent to 44 mg/ m&sup2; of daunorubicin and 100 mg/m&sup2; of cytarabine).on days 1, 3, and 5 show the mean AUClast metabolite:parent ratio for daunorubicinol and AraU were 1.79% and 3.22% to that for daunorubicin and cytarabine, respectively; which are lower than those typically reported for non-liposomal products, ~40-60% for daunorubicinol:daunorubicin and ~80% for AraU:cytarabine. The lower percentages of metabolite:parent ratios after Vyxeos liposomal administration indicate that most of the total daunorubicin and cytarabine in the circulation is trapped inside the Vyxeos liposomal liposomes, where they are inaccessible to medicinal product-metabolising enzymes.</p><p>Elimination<br />Vyxeos liposomal exhibits a prolonged half-life (%CV) of 31.5 h (28.5%) for daunorubicin and 40.4 h (24.2%) for cytarabine with greater than 99% of the daunorubicin and cytarabine in the plasma remaining encapsulated within the liposomes. The clearance (%CV) is 0.16 L/h (53.3%) for daunorubicin and 0.13 L/h (60.2%) for cytarabine.</p><p>Urinary excretion of daunorubicin and daunorubicinol accounts for 9% of the administered dose of daunorubicin, and urinary excretion of cytarabine and AraU accounts for 71% of the administered dose of cytarabine.</p><p>Special populations<br />Age, sex, race, body weight, body mass index, and white blood cell count do not have a clinically important effect on the exposure of total daunorubicin or cytarabine after adjusting dose by body surface area.</p><p>Paediatric population<br />Insufficient pharmacokinetic data were collected in paediatric patients to draw conclusions.</p><p>Elderly population<br />The pharmacokinetics of Vyxeos liposomal in patients aged &gt; 85 years has not yet been evaluated. No data are available.</p><p>Hepatic impairment<br />The pharmacokinetics of total daunorubicin and cytarabine were not altered in patients with bilirubin &le; 50 &mu;mol/L. The pharmacokinetics in patients with bilirubin greater than 50 &mu;mol/L is unknown.</p><p>Renal impairment<br />Based on a population pharmacokinetic analysis using data from clinical studies in patients, no significant difference in clearance of daunorubicin or cytarabine was observed in patients with pre-existing mild to moderate renal impairment (60 mL/min &ge; to &le; 89 mL/min creatinine clearance [CrCL] for mild, and 30 mL/min &ge; to &le; 59 mL/min creatinine clearance [CrCL] for moderate) compared to patients with baseline normal renal function (CrCL &ge; 90 mL/min). The potential effects of severe renal impairment (CrCL 15 mL/min &ge; to &le; 29 mL/min, C-G) and end-stage renal disease on the pharmacokinetics of daunorubicin and cytarabine administered as Vyxeos liposomal are unknown</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat-dose toxicity of Vyxeos liposomal was tested in two-cycle intravenous infusion toxicity studies with 28-day recovery periods conducted in rats and dogs. Adverse effects of Vyxeos liposomal occurred at all tested dose levels (low to null safety margins as based on systemic exposures) and were generally consistent with those known for non-liposomal daunorubicin and/or cytarabine, comprising mainly findings of gastrointestinal and hematological toxicity. Although central nervous system (CNS) and cardiovascular system parameters were included in these studies, given the observed morbidity and mortality, there was insufficient information to arrive at an integrated assessment of safety pharmacology of Vyxeos liposomal. Vyxeos liposomal contains daunorubicin, which is known for its profound cardiotoxicity potential, and cytarabine, which is known to be associated with CNS toxicities.</p><p>Carcinogenicity, mutagenicity, and reproductive toxicity studies have not been conducted with Vyxeos liposomal.</p><p>While cytarabine is not a carcinogen, daunorubicin is a possible carcinogen, hence, Vyxeos liposomal may be associated with a carcinogenic potential. Both daunorubicin and cytarabine are genotoxic, therefore, Vyxeos liposomal may be associated with a genotoxic risk.</p><p>A high incidence of mammary tumours was observed about 120 days after a single intravenous dose of daunorubicin in rats (at about 1.7 times the human dose on a mg/m2 basis). Daunorubicin was mutagenic in in vitro tests (Ames assay, V79 hamster cell assay), and clastogenic in vitro (CCRF-CEM human lymphoblasts) and in vivo (SCE assay in mouse bone marrow) tests.</p><p>Cytarabine was mutagenic in in vitro tests and was clastogenic in vitro (chromosome aberrations and SCE in human leukocytes) and in vivo (chromosome aberrations and SCE assay in rodent bone marrow, mouse micronucleus assay). Cytarabine caused the transformation of hamster embryo cells and rat H43 cells in vitro.</p><p>Cytarabine was clastogenic to meiotic cells.</p><p>Both cytarabine and daunorubicin, tested separately, showed teratogenic and embryotoxic effects in animal studies. Furthermore, daunorubicin caused testicular atrophy and total aplasia of spermatocytes in the seminiferous tubules in dogs and cytarabine, sperm-head abnormalities in mice. A single dose of cytarabine in rats, administered on day 14 of gestation, reduced prenatal and postnatal brain size and caused permanent impairment of learning ability.</p><p>Environmental risk assessment (ERA)<br />Environmental risk assessment has shown that Vyxeos liposomal is not anticipated to have the potential to be persistent, bioaccumulative, or toxic to the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distearoylphosphatidylcholine<br />Distearoylphosphatidylglycerol<br />Cholesterol<br />Copper gluconate<br />Trolamine (for pH adjustment)<br />Sucrose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
2 years.

Stability of reconstituted suspension in the vial
Chemical and physical in-use stability has been demonstrated for 4 hours at 2°C to 8°C when kept in an upright position.
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
Stability of diluted infusion solution
Chemical and physical in-use stability has been demonstrated for 4 hours at 2°C to 8°C.
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
The maximum combined storage time for reconstituted product in the vial and reconstituted product diluted into an infusion bag is up to 4 hours at 2°C to 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />Keep the vial in the original carton in order to protect from light. Store in an upright position.<br />For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 mL vial (type 1 glass) with a stopper (chlorobutyl rubber), and an overseal (aluminium) containing 44 mg daunorubicin and 100 mg cytarabine.<br />Each pack contains either 1 vial, 2 vials or 5 vials. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vyxeos liposomal is a cytotoxic medicinal product. Applicable special handling and disposal procedures should be followed. The product is intended for single use only. Any unused product should be disposed of in accordance with local requirements for cytotoxic agents.</p><p>Preparation instructions<br />&bull; Determine the dose and number of vials of Vyxeos liposomal based on the individual patient&rsquo;s BSA as outlined in section 4.2.<br />&bull; Remove the appropriate number of vials of Vyxeos liposomal from the refrigerator and equilibrate to the room temperature (15C to 30C) for 30 minutes.<br />&bull; Then, reconstitute each vial with 19 mL of sterile water for injections using a 20 mL syringe, and immediately thereafter start a 5-minute timer.<br />&bull; Carefully swirl the contents of the vial for 5 minutes while gently inverting the vial every 30 seconds.<br />&bull; Do not heat, vortex, or shake vigorously.<br />&bull; After reconstitution, let it rest for 15 minutes.<br />&bull; The reconstituted product should be an opaque, purple, homogeneous dispersion, essentially free from visual particulates.<br />&bull; If the reconstituted product is not diluted into an infusion bag immediately, store in a refrigerator (2&ordm;C to 8&ordm;C) for up to 4 hours.<br />&bull; Following the storage of reconstituted product in the vial for up to 4 hours at 2&deg;C to 8&deg;C in an upright position, the reconstituted product must immediately be diluted into an infusion solution and run for the 90-minute infusion time.<br />o Reconstituted product in the vial and reconstituted product which has been diluted into an infusion solution are stable for a maximum combined storage time of up to 4 hours when stored at 2&deg;C to 8&deg;C, The 4-hour stability period for the reconstituted product in the vial does not allow for an additional 4-hour stability period after the appropriate dose from the reconstituted vial is diluted into the infusion solution.<br />o The 4-hour stability period when reconstituted product diluted into the infusion bag is stored at 2&deg;C to 8&deg;C does not include the time required for reconstitution or the 90-minute infusion time.<br />o The diluted infusion solution must be immediately infused for the 90-minute infusion time following the up to 4-hour stability period.<br />&bull; Calculate the volume of reconstituted Vyxeos liposomal required using the following formula:<br />[volume required (mL) = dose of daunorubicin (mg/m2) x patient&rsquo;s BSA (m2)/2.2 (mg/mL)]. The concentration of the reconstituted solution is 44 mg/20 mL (2.2 mg/mL) daunorubicin and 100 mg/20 mL (5 mg/mL) cytarabine.</p><p>-Gently invert each vial 5 times prior to withdrawing the concentrate for dilution.<br />&bull; Aseptically withdraw the calculated volume of reconstituted Vyxeos liposomal from the vial(s) with a sterile syringe and transfer it to an infusion bag containing 500 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, or 5% glucose. There may be residual product remaining in the vial. Discard unused portion.<br />&bull; Gently invert the bag to mix the solution. The dilution of the reconstituted product results in a deep purple, translucent, homogeneous dispersion.<br />&bull; If the diluted infusion solution is not used immediately, store in a refrigerator (2&deg;C to 8&deg;C) for up to 4 hours.<br />&bull; Gently invert the bag to mix the solution after refrigeration.</p><p>Administration instructions<br />&bull; Do not mix Vyxeos liposomal with, or administer as an infusion with, other medicinal products.<br />&bull; Administer Vyxeos liposomal by constant intravenous infusion over 90 minutes via an infusion pump through a central venous catheter or a peripherally inserted central catheter. An in-line membrane filter may be used for the intravenous infusion of Vyxeos liposomal, provided the minimum pore diameter of the filter is greater than or equal to 15 &mu;m.<br />&bull; Flush the line after administration with sodium chloride 9 mg/mL (0.9%) solution for injection.</p><p>This medicinal product could have potential risk for the environment due to the cytotoxic and antimitotic activities, which could induce possible reproductive effects. All materials used for dilution and administration should be disposed of according to local procedures applicable to the discarding of antineoplastic agents. Any unused medicinal product or waste material should be disposed of in accordance with local requirements for cytotoxic agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazz Pharmaceuticals Ireland Ltd
5th Floor
Waterloo Exchange
Waterloo Road
Dublin
D04 E5W7
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Detailed information on this medicinal product is available on the website of the European Medicines
Agency http://www.ema.europa.eu
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>